Europe
Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.
The U.K’s MHRA has granted conditional authorization to Moderna’s newest vaccine candidate, making it the first Omicron-specific COVID-19 booster vaccine approved by a regulatory agency.
Researchers have found that the use of a cell phone technology-based polytherapeutic that delivers white noise can improve symptoms for people suffering from tinnitus.
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
When GSK’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.
Hyloris did not provide details on the FDA’s concern regarding Maxigesic IV but said it will fully comply with whatever is necessary to move the product forward.
Swiss biopharma giant Novartis plans to cut up to 8,000 jobs in hopes of saving at least $1 billion by 2024.
It’s been a busy month for big biopharma companies looking to expand operations with Moderna, AstraZeneca, Sanofi and more are setting up new facilities internationally.
The WHO will decide whether to declare a public health emergency following the recent outbreaks of monkeypox, and poliovirus has been detected in London water samples.
Olink said the measurement of proteins at “population scale” provides the ability to improve the understanding of underlying mechanisms of diseases.
PRESS RELEASES